Skip to main content
. 2017 Feb 17;13:515–526. doi: 10.2147/NDT.S120190

Table 3.

Summary of TEAEs in >2 patients (safety set)

Treatment-emergent adverse events, n (%) Total (N=302)
Headache 12 (3.97)
Nasopharyngitis 11 (3.64)
Nausea 9 (2.98)
Dizziness 8 (2.65)
Abdominal discomfort 5 (1.66)
Diarrhea 4 (1.32)
Insomnia 4 (1.32)
Dysphoria 3 (0.99)
Anxiety 3 (0.99)
Weight gain 3 (0.99)
Transaminase increased 3 (0.99)
Lassitude 3 (0.99)

Abbreviations: N, total sample size; n, number of occurrence of TEAEs; TEAE, treatment-emergent adverse event.